

Accepted Manuscript

Full length article

Controlled Release of an HDAC Inhibitor for Reduction of Inflammation in Dry Eye Disease

Michelle L. Ratay, Stephen C. Balmert, Ethan J. Bassin, Steven R. Little

PII: S1742-7061(18)30122-3

DOI: <https://doi.org/10.1016/j.actbio.2018.03.002>

Reference: ACTBIO 5344

To appear in: *Acta Biomaterialia*


Received Date: 27 November 2017

Revised Date: 24 February 2018

Accepted Date: 1 March 2018

Please cite this article as: Ratay, M.L., Balmert, S.C., Bassin, E.J., Little, S.R., Controlled Release of an HDAC Inhibitor for Reduction of Inflammation in Dry Eye Disease, *Acta Biomaterialia* (2018), doi: <https://doi.org/10.1016/j.actbio.2018.03.002>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Controlled Release of an HDAC Inhibitor for Reduction of Inflammation
in Dry Eye Disease**

Michelle L. Ratay^a, Stephen C. Balmert^a, Ethan J. Bassin^c, and Steven R. Little^{a,b,c,d,e,*}

^aDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261

^bDepartment of Chemical Engineering, University of Pittsburgh, Pittsburgh, PA 15216

^cDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA 15213

^dDepartment of Ophthalmology, University of Pittsburgh, Pittsburgh, PA 15213

^eDepartment of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh PA 15261

***To whom correspondence may be addressed. Email: srlittle@pitt.edu**

Key Words: HDACi, SAHA, Microspheres, PLGA, dry eye disease

Abstract

Dry eye disease (DED), also known as keratoconjunctivitis sicca, is an ocular surface disease characterized by T-cell-mediated inflammation. Current therapeutics, such as immunosuppressive agents, act to suppress the clinical signs and inflammation. However, long-term usage of these treatments can cause severe side effects. In this study, we present an alternative therapeutic approach that utilizes a histone deacetylase inhibitor (HDACi) to regulate transcription of a variety of immunomodulatory genes. Specifically, HDACi have emerged as a potential anti-inflammatory agent, which can modulate the functions of a subset of suppressive T lymphocytes known as regulatory T cells (Tregs), enhancing FoxP3 acetylation and subsequently guarding the transcription factor from proteasomal degradation. Here, a specific HDACi known as SAHA (suberoylanilide hydroxamic acid) was formulated to controllably release in the lacrimal gland. Intralacrimal gland injection of PLGA-based SAHA microspheres prevented

Download English Version:

<https://daneshyari.com/en/article/6482961>

Download Persian Version:

<https://daneshyari.com/article/6482961>

[Daneshyari.com](https://daneshyari.com)